Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 67 entries
Sorted by: Best Match Show Resources per page
Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey.

Clinical and translational allergy

Bygum A, Caballero T, Grumach AS, Longhurst HJ, Bouillet L, Aberer W, Zanichelli A, Botha J, Andresen I, Maurer M.
PMID: 31360439
Clin Transl Allergy. 2019 Jul 19;9:37. doi: 10.1186/s13601-019-0272-9. eCollection 2019.

BACKGROUND: Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling in subcutaneous or submucosal tissues. Symptoms often begin by age 5-11 years and worsen during puberty, but attacks can occur at any age and recur throughout...

Cite
Bygum A, Caballero T, Grumach AS, et al. Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey. Clin Transl Allergy. 2019;9:37doi: 10.1186/s13601-019-0272-9.
Bygum, A., Caballero, T., Grumach, A. S., Longhurst, H. J., Bouillet, L., Aberer, W., Zanichelli, A., Botha, J., Andresen, I., Maurer, M. (2019). Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey. Clinical and translational allergy, 937. https://doi.org/10.1186/s13601-019-0272-9
Bygum, Anette, et al. "Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey." Clinical and translational allergy vol. 9 (2019): 37. doi: https://doi.org/10.1186/s13601-019-0272-9
Bygum A, Caballero T, Grumach AS, Longhurst HJ, Bouillet L, Aberer W, Zanichelli A, Botha J, Andresen I, Maurer M. Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey. Clin Transl Allergy. 2019 Jul 19;9:37. doi: 10.1186/s13601-019-0272-9. eCollection 2019. PMID: 31360439; PMCID: PMC6639901.
Copy Download .nbib Format: NLM
[POINTS OF REVISE IN THE INTERNATIONAL WAO/EAACI GUIDELINE FOR THE MANAGEMENT OF HEREDITARY ANGIOEDEMA-THE 2017 REVISION AND UPDATE].

Arerugi = [Allergy]

Hide M.
PMID: 30787237
Arerugi. 2019;68(1):16-19. doi: 10.15036/arerugi.68.16.

No abstract available.

Cite
Hide M. [POINTS OF REVISE IN THE INTERNATIONAL WAO/EAACI GUIDELINE FOR THE MANAGEMENT OF HEREDITARY ANGIOEDEMA-THE 2017 REVISION AND UPDATE]. Arerugi. 2019;68(1):16-19doi: 10.15036/arerugi.68.16.
Hide, M. (2019). [POINTS OF REVISE IN THE INTERNATIONAL WAO/EAACI GUIDELINE FOR THE MANAGEMENT OF HEREDITARY ANGIOEDEMA-THE 2017 REVISION AND UPDATE]. Arerugi = [Allergy], 68(1), 16-19. https://doi.org/10.15036/arerugi.68.16
Hide, Michihiro. "[POINTS OF REVISE IN THE INTERNATIONAL WAO/EAACI GUIDELINE FOR THE MANAGEMENT OF HEREDITARY ANGIOEDEMA-THE 2017 REVISION AND UPDATE]." Arerugi = [Allergy] vol. 68,1 (2019): 16-19. doi: https://doi.org/10.15036/arerugi.68.16
Hide M. [POINTS OF REVISE IN THE INTERNATIONAL WAO/EAACI GUIDELINE FOR THE MANAGEMENT OF HEREDITARY ANGIOEDEMA-THE 2017 REVISION AND UPDATE]. Arerugi. 2019;68(1):16-19. doi: 10.15036/arerugi.68.16. Japanese. PMID: 30787237.
Copy Download .nbib Format: NLM
Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in Intubated Patients: Case Series and Literature Review.

Case reports in critical care

Yeung EK, Saikumar H, Castaneda-Nerio J, Adams SG, Wong M.
PMID: 29686908
Case Rep Crit Care. 2018 Mar 04;2018:8081607. doi: 10.1155/2018/8081607. eCollection 2018.

PURPOSE: A case series of icatibant use in intubated patients with angiotensin-converting enzyme inhibitor- (ACEI-) induced angioedema is presented along with a relevant literature review and recommendations for utilization.SUMMARY: Three intubated patients admitted to the intensive care unit for...

Cite
Yeung EK, Saikumar H, Castaneda-Nerio J, et al. Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in Intubated Patients: Case Series and Literature Review. Case Rep Crit Care. 2018;2018:8081607doi: 10.1155/2018/8081607.
Yeung, E. K., Saikumar, H., Castaneda-Nerio, J., Adams, S. G., & Wong, M. (2018). Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in Intubated Patients: Case Series and Literature Review. Case reports in critical care, 20188081607. https://doi.org/10.1155/2018/8081607
Yeung, Erin K, et al. "Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in Intubated Patients: Case Series and Literature Review." Case reports in critical care vol. 2018 (2018): 8081607. doi: https://doi.org/10.1155/2018/8081607
Yeung EK, Saikumar H, Castaneda-Nerio J, Adams SG, Wong M. Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in Intubated Patients: Case Series and Literature Review. Case Rep Crit Care. 2018 Mar 04;2018:8081607. doi: 10.1155/2018/8081607. eCollection 2018. PMID: 29686908; PMCID: PMC5857324.
Copy Download .nbib Format: NLM
Diagnosis and screening of patients with hereditary angioedema in primary care.

Therapeutics and clinical risk management

Henao MP, Kraschnewski JL, Kelbel T, Craig TJ.
PMID: 27194914
Ther Clin Risk Manag. 2016 May 02;12:701-11. doi: 10.2147/TCRM.S86293. eCollection 2016.

Hereditary angioedema (HAE) is a rare autosomal dominant disease that commonly manifests with episodes of cutaneous or submucosal angioedema and intense abdominal pain. The condition usually presents due to a deficiency of C1 esterase inhibitor (C1-INH) that leads to...

Cite
Henao MP, Kraschnewski JL, Kelbel T, et al. Diagnosis and screening of patients with hereditary angioedema in primary care. Ther Clin Risk Manag. 2016;12:701-11doi: 10.2147/TCRM.S86293.
Henao, M. P., Kraschnewski, J. L., Kelbel, T., & Craig, T. J. (2016). Diagnosis and screening of patients with hereditary angioedema in primary care. Therapeutics and clinical risk management, 12701-11. https://doi.org/10.2147/TCRM.S86293
Henao, Maria Paula, et al. "Diagnosis and screening of patients with hereditary angioedema in primary care." Therapeutics and clinical risk management vol. 12 (2016): 701-11. doi: https://doi.org/10.2147/TCRM.S86293
Henao MP, Kraschnewski JL, Kelbel T, Craig TJ. Diagnosis and screening of patients with hereditary angioedema in primary care. Ther Clin Risk Manag. 2016 May 02;12:701-11. doi: 10.2147/TCRM.S86293. eCollection 2016. PMID: 27194914; PMCID: PMC4859422.
Copy Download .nbib Format: NLM
High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study.

Orphanet journal of rare diseases

Squeglia V, Barbarino A, Bova M, Gravante C, Petraroli A, Spadaro G, Triggiani M, Genovese A, Marone G.
PMID: 27686124
Orphanet J Rare Dis. 2016 Sep 29;11(1):133. doi: 10.1186/s13023-016-0518-8.

BACKGROUND: Hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) is characterized by recurrent attacks of swelling that affect various body sites. Such attacks are a frequent cause of visits to the emergency department and are often treated in the hospital. In...

Cite
Squeglia V, Barbarino A, Bova M, et al. High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study. Orphanet J Rare Dis. 2016;11(1):133doi: 10.1186/s13023-016-0518-8.
Squeglia, V., Barbarino, A., Bova, M., Gravante, C., Petraroli, A., Spadaro, G., Triggiani, M., Genovese, A., & Marone, G. (2016). High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study. Orphanet journal of rare diseases, 11(1), 133. https://doi.org/10.1186/s13023-016-0518-8
Squeglia, Veronica, et al. "High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study." Orphanet journal of rare diseases vol. 11,1 (2016): 133. doi: https://doi.org/10.1186/s13023-016-0518-8
Squeglia V, Barbarino A, Bova M, Gravante C, Petraroli A, Spadaro G, Triggiani M, Genovese A, Marone G. High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study. Orphanet J Rare Dis. 2016 Sep 29;11(1):133. doi: 10.1186/s13023-016-0518-8. PMID: 27686124; PMCID: PMC5043538.
Copy Download .nbib Format: NLM
On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

Aygören-Pürsün E, Martinez-Saguer I, Rusicke E, Klingebiel T, Kreuz W.
PMID: 20667124
Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):21. doi: 10.1186/1710-1492-6-21.

BACKGROUND: Manifestation of acute edema in hereditary angioedema (HAE) is characterized by interindividual and intraindividual variability in symptom expression over time. Flexible therapy options are needed.METHODS: We describe and report on the outcomes of the highly individualized approach to...

Cite
Aygören-Pürsün E, Martinez-Saguer I, Rusicke E, et al. On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience. Allergy Asthma Clin Immunol. 2010;6(1):21doi: 10.1186/1710-1492-6-21.
Aygören-Pürsün, E., Martinez-Saguer, I., Rusicke, E., Klingebiel, T., & Kreuz, W. (2010). On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 6(1), 21. https://doi.org/10.1186/1710-1492-6-21
Aygören-Pürsün, Emel, et al. "On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience." Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology vol. 6,1 (2010): 21. doi: https://doi.org/10.1186/1710-1492-6-21
Aygören-Pürsün E, Martinez-Saguer I, Rusicke E, Klingebiel T, Kreuz W. On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience. Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):21. doi: 10.1186/1710-1492-6-21. PMID: 20667124; PMCID: PMC2920239.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 20664824
Methods Find Exp Clin Pharmacol. 2010 Jun;32(5):331-88. doi: 10.1358/mf.2010.32.5.1520420.

[¹¹C]RAC; (18)F-Fluoromisonidazole; 89-12; 9-[¹⁸F]Fluoropropyl-(+)-dihydrotetrabenazine; Adalimumab, Adecatumumab, ADMVA, ADXS-11-001, Aflibercept, Agatolimod sodium, AGS-004, Alglucosidase alfa, Aliskiren fumarate, Alvocidib hydrochloride, AMG-108, AMG-853, Apixaban, Aripiprazole, Armodafinil, Atazanavir sulfate, Atomoxetine hydrochloride; Bevacizumab, BioMatrix Flex drug eluting stent, Biphasic insulin aspart, Bortezomib, Bosentan; Caspofungin...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010;32(5):331-88doi: 10.1358/mf.2010.32.5.1520420.
Tomillero, A., & Moral, M. A. (2010). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 32(5), 331-88. https://doi.org/10.1358/mf.2010.32.5.1520420
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 32,5 (2010): 331-88. doi: https://doi.org/10.1358/mf.2010.32.5.1520420
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jun;32(5):331-88. doi: 10.1358/mf.2010.32.5.1520420. PMID: 20664824.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X.
PMID: 18389098
Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):67-99.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prouse Science Integrity, the drug...

Cite
Bayés M, Rabasseda X. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008;30(1):67-99
Bayés, M., & Rabasseda, X. (2008). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 30(1), 67-99.
Bayés, M, and Rabasseda, X. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 30,1 (2008): 67-99.
Bayés M, Rabasseda X. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):67-99. PMID: 18389098.
Copy Download .nbib Format: NLM
Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials.

Clinical and translational allergy

Bucher MC, Petkovic T, Helbling A, Steiner UC.
PMID: 28861213
Clin Transl Allergy. 2017 Aug 31;7:27. doi: 10.1186/s13601-017-0164-9. eCollection 2017.

BACKGROUND: Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease for which there are no available laboratory parameters to clearly define the disorder. Therapy is often difficult and various treatment options have been proposed. In this paper, we have...

Cite
Bucher MC, Petkovic T, Helbling A, et al. Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials. Clin Transl Allergy. 2017;7:27doi: 10.1186/s13601-017-0164-9.
Bucher, M. C., Petkovic, T., Helbling, A., & Steiner, U. C. (2017). Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials. Clinical and translational allergy, 727. https://doi.org/10.1186/s13601-017-0164-9
Bucher, Martin Christian, et al. "Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials." Clinical and translational allergy vol. 7 (2017): 27. doi: https://doi.org/10.1186/s13601-017-0164-9
Bucher MC, Petkovic T, Helbling A, Steiner UC. Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials. Clin Transl Allergy. 2017 Aug 31;7:27. doi: 10.1186/s13601-017-0164-9. eCollection 2017. PMID: 28861213; PMCID: PMC5577688.
Copy Download .nbib Format: NLM
Icatibant in the treatment of Angiotensin-converting enzyme inhibitor-induced angioedema.

Case reports in critical care

Crooks NH, Patel J, Diwakar L, Smith FG.
PMID: 25328718
Case Rep Crit Care. 2014;2014:864815. doi: 10.1155/2014/864815. Epub 2014 Sep 23.

We describe the case of a 75-year-old woman who presented with massive tongue and lip swelling secondary to angiotensin-converting enzyme inhibitor-induced angioedema. An awake fibre-optic intubation was performed because of impending airway obstruction. As there was no improvement in...

Cite
Crooks NH, Patel J, Diwakar L, et al. Icatibant in the treatment of Angiotensin-converting enzyme inhibitor-induced angioedema. Case Rep Crit Care. 2014;2014:864815doi: 10.1155/2014/864815.
Crooks, N. H., Patel, J., Diwakar, L., & Smith, F. G. (2014). Icatibant in the treatment of Angiotensin-converting enzyme inhibitor-induced angioedema. Case reports in critical care, 2014864815. https://doi.org/10.1155/2014/864815
Crooks, Neil H, et al. "Icatibant in the treatment of Angiotensin-converting enzyme inhibitor-induced angioedema." Case reports in critical care vol. 2014 (2014): 864815. doi: https://doi.org/10.1155/2014/864815
Crooks NH, Patel J, Diwakar L, Smith FG. Icatibant in the treatment of Angiotensin-converting enzyme inhibitor-induced angioedema. Case Rep Crit Care. 2014;2014:864815. doi: 10.1155/2014/864815. Epub 2014 Sep 23. PMID: 25328718; PMCID: PMC4189935.
Copy Download .nbib Format: NLM
Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema.

Journal of clinical pharmacology

Wang Y, Jomphe C, Marier JF, Martin P.
PMID: 33091166
J Clin Pharmacol. 2021 Apr;61(4):555-564. doi: 10.1002/jcph.1768. Epub 2020 Oct 22.

Elevated bradykinin levels are responsible for the development of clinical symptoms in patients with hereditary angioedema (HAE). Icatibant is a bradykinin type 2 receptor antagonist indicated for the acute treatment of HAE attacks. A population modeling and simulation approach...

Cite
Wang Y, Jomphe C, Marier JF, et al. Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema. J Clin Pharmacol. 2020;61(4):555-564doi: 10.1002/jcph.1768.
Wang, Y., Jomphe, C., Marier, J. F., & Martin, P. (2021). Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema. Journal of clinical pharmacology, 61(4), 555-564. https://doi.org/10.1002/jcph.1768
Wang, Yi, et al. "Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema." Journal of clinical pharmacology vol. 61,4 (2021): 555-564. doi: https://doi.org/10.1002/jcph.1768
Wang Y, Jomphe C, Marier JF, Martin P. Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema. J Clin Pharmacol. 2021 Apr;61(4):555-564. doi: 10.1002/jcph.1768. Epub 2020 Oct 22. PMID: 33091166; PMCID: PMC7984404.
Copy Download .nbib Format: NLM
EFFECT OF EARLY BLOCKADE OF BRADYKININ B2-RECEPTORS ON THE BLOOD PRESSURE PHENOTYPE OF NORMOTENSIVE AND SPONTANEOUSLY HYPERTENSIVE RATS.

Pharmacological research

Emanueli C, Madeddu P.
PMID: 9356202
Pharmacol Res. 1997 Jun;35(6):523-6.

We evaluated if chronic blockade of bradykinin B2-receptors by the long-acting antagonist Icatibant (D-Arg,'Hyp3,Thi5,D-Tic7,Oic8'-bradykinin) affects blood pressure of rats. Pairs of normotensive Wistar Kyoto rats or spontaneously hypertensive rats were mated and their offspring received Icatibant (25 nmol day-1...

Cite
Emanueli C, Madeddu P. EFFECT OF EARLY BLOCKADE OF BRADYKININ B2-RECEPTORS ON THE BLOOD PRESSURE PHENOTYPE OF NORMOTENSIVE AND SPONTANEOUSLY HYPERTENSIVE RATS. Pharmacol Res. 1997;35(6):523-6
Emanueli, C., & Madeddu, P. (1997). EFFECT OF EARLY BLOCKADE OF BRADYKININ B2-RECEPTORS ON THE BLOOD PRESSURE PHENOTYPE OF NORMOTENSIVE AND SPONTANEOUSLY HYPERTENSIVE RATS. Pharmacological research, 35(6), 523-6.
Emanueli, and Madeddu. "EFFECT OF EARLY BLOCKADE OF BRADYKININ B2-RECEPTORS ON THE BLOOD PRESSURE PHENOTYPE OF NORMOTENSIVE AND SPONTANEOUSLY HYPERTENSIVE RATS." Pharmacological research vol. 35,6 (1997): 523-6.
Emanueli C, Madeddu P. EFFECT OF EARLY BLOCKADE OF BRADYKININ B2-RECEPTORS ON THE BLOOD PRESSURE PHENOTYPE OF NORMOTENSIVE AND SPONTANEOUSLY HYPERTENSIVE RATS. Pharmacol Res. 1997 Jun;35(6):523-6. PMID: 9356202.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 67 entries